These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21474462)

  • 1. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting.
    Cowie MR; Cure S; Bianic F; McGuire A; Goodall G; Tavazzi L
    Eur J Heart Fail; 2011 Jun; 13(6):681-9. PubMed ID: 21474462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
    J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk.
    Fairbairn TA; Meads DM; Hulme C; Mather AN; Plein S; Blackman DJ; Greenwood JP
    Heart; 2013 Jul; 99(13):914-20. PubMed ID: 23696198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).
    Sanders-van Wijk S; van Asselt AD; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Vuillomenet A; Peter M; Pfisterer ME; Brunner-La Rocca HP;
    JACC Heart Fail; 2013 Feb; 1(1):64-71. PubMed ID: 24621800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
    Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
    Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
    Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
    Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
    Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
    J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.
    Caro JJ; Guo S; Ward A; Chalil S; Malik F; Leyva F
    Curr Med Res Opin; 2006 Jun; 22(6):1171-9. PubMed ID: 16846550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study.
    Maru S; Byrnes JM; Carrington MJ; Stewart S; Scuffham PA
    J Med Econ; 2017 Apr; 20(4):318-327. PubMed ID: 27841726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis.
    Perez A; Touchette DR; DiDomenico RJ; Stamos TD; Walton SM
    Pharmacotherapy; 2011 Jun; 31(6):552-65. PubMed ID: 21923439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.
    Rosen VM; Taylor DC; Parekh H; Pandya A; Thompson D; Kuznik A; Waters DD; Drummond M; Weinstein MC
    Pharmacoeconomics; 2010; 28(1):47-60. PubMed ID: 20014876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.